{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:57:00Z","timestamp":1782763020172,"version":"3.54.5"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mayo K2R award"},{"DOI":"10.13039\/100011542","name":"CCaTS","doi-asserted-by":"publisher","award":["UL1TR002377"],"award-info":[{"award-number":["UL1TR002377"]}],"id":[{"id":"10.13039\/100011542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>An increasing number of cancer patients are benefiting from long term cancer-directed therapy with an ever-expanding arsenal of novel agents from monoclonal antibodies to small molecules and cellular therapies in addition to the mainstay cytotoxic chemotherapy. All these therapies are accompanied by a unique array of adverse events, which include kidney toxicity. In this context, the need for onco-nephrology expertise continues to grow. Oncologists and hematologists collaborate closely with onco-nephrologists to determine: (i) treatment options for special populations based on accurate assessment of patients\u2019 glomerular filtration rate, (ii) supportive therapies for those whose treatment course is complicated by acute kidney injury, and (iii) pharmacologic strategies to continue or restart cancer therapy during kidney dysfunction. Here we outline 10 tips for common clinical scenarios in an outpatient onco-nephrology clinic.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf174","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T16:54:50Z","timestamp":1748537690000},"source":"Crossref","is-referenced-by-count":1,"title":["Ten tips for an onco-nephrology clinic"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8146-0268","authenticated-orcid":false,"given":"Elena-Bianca","family":"Barbir","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic Department of Internal Medicine, , Rochester, MN , USA"},{"name":"Division of Nephrology and Transplant, University of Alberta Department of Internal Medicine, , Edmonton , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic Department of Internal Medicine, , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic Department of Internal Medicine, , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2025063005211286400_bib1","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.34067\/KID.0000000000000495","article-title":"Onconephrology Fellowship training: current status and future outlook","volume":"5","author":"Bonilla","year":"2024","journal-title":"Kidney360"},{"key":"2025063005211286400_bib2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.nefroe.2021.04.006","article-title":"Monographic consultation of onconephrology. Rationale and implementation","volume":"41","author":"Alonso","year":"2021","journal-title":"Nefrolog\u00eda"},{"key":"2025063005211286400_bib3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2215\/CJN.10960917","article-title":"Clinical pharmacodynamics: principles of drug response and alterations in kidney disease","volume":"13","author":"Keller","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025063005211286400_bib4","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","article-title":"Assessment of GFR in patients with cancer: a statement from the American Society of Onco-Nephrology","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025063005211286400_bib5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.kint.2024.06.012","article-title":"Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102)","volume":"106","author":"Dorshow","year":"2024","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.kint.2024.06.029","article-title":"Iohexol plasma clearance measurement protocol standardization for adults: a consensus paper of the European Kidney Function Consortium","volume":"106","author":"Ebert","year":"2024","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib7","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1681\/ASN.2009020171","article-title":"Measured GFR as a confirmatory test for estimated GFR","volume":"20","author":"Stevens","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025063005211286400_bib8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","article-title":"Measurement and estimation of GFR for use in clinical practice: core curriculum 2021","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2025063005211286400_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt.729","article-title":"Assessment of glomerular filtration rate in health and disease: a state of the art review","volume":"102","author":"Levey","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2025063005211286400_bib10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2025063005211286400_bib11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"2025063005211286400_bib12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025063005211286400_bib13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41581-024-00852-y","article-title":"Cystatin C and the misdiagnosis of CKD in older adults","volume":"20","author":"Rule","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2025063005211286400_bib14","doi-asserted-by":"publisher","first-page":"100347","DOI":"10.1016\/j.xgen.2023.100347","article-title":"Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy","volume":"3","author":"Kleeman","year":"2023","journal-title":"Cell Genomics"},{"key":"2025063005211286400_bib15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/23993693221114901","article-title":"Serum cystatin C level can be used to estimate GFR in patients with solid tumors: moderator Commentary","volume":"6","author":"Vanhoutte","year":"2022","journal-title":"J Onco-Nephrolo"},{"key":"2025063005211286400_bib16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2021.04.009","article-title":"Capmatinib-induced pseudo-acute kidney injury: a case report","volume":"79","author":"Mohan","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025063005211286400_bib17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.kint.2021.12.010","article-title":"A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors","volume":"101","author":"Costa","year":"2022","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1681\/ASN.20233411S126d","article-title":"Performance of creatinine and cystatin C-based equations among patients with hematological or solid cancers: real-world data from a clinical cohort: TH-OR92","volume":"34","author":"Titan","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025063005211286400_bib19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2215\/CJN.0000000616","article-title":"Performance of creatinine and cystatin-based equations on estimating measured GFR in people with hematological and solid cancers","volume":"20","author":"Titan","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025063005211286400_bib20","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.ackd.2008.04.003","article-title":"Biomarkers of acute kidney injury","volume":"15","author":"Edelstein","year":"2008","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025063005211286400_bib22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2215\/CJN.0000000000000509","article-title":"Assessment of GFR in patients with cancer part 2: anticancer therapies-perspectives from the American Society of Onco-Nephrology (ASON)","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025063005211286400_bib23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025063005211286400_bib24","doi-asserted-by":"publisher","first-page":"e171431","DOI":"10.1172\/JCI171431","article-title":"Biomarkers in acute kidney injury: on the cusp of a new era?","volume":"133","author":"Canney","year":"2023","journal-title":"J Clin Invest"},{"key":"2025063005211286400_bib25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/ckj\/sfad011","article-title":"Pseudo-AKI associated with targeted anti-cancer agents\u2014the truth is in the eye of the filtration marker","volume":"16","author":"Vanhoutte","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025063005211286400_bib26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"2025063005211286400_bib27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jtho.2023.09.1444","article-title":"Brief report: tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to \u201cfalse\u201d decreases in renal function","volume":"19","author":"Chen","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2025063005211286400_bib28","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/life13061264","article-title":"Drug-induced podocytopathies: report of four cases and review of the literature","volume":"13","author":"Athanasopoulou","year":"2023","journal-title":"Life"},{"key":"2025063005211286400_bib29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/nep.13086","article-title":"Cabozantinib-induced renal thrombotic microangiopathy","volume":"23","author":"La Manna","year":"2018","journal-title":"Nephrology"},{"key":"2025063005211286400_bib30","doi-asserted-by":"publisher","first-page":"9237","DOI":"10.1038\/s41598-018-27672-y","article-title":"Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1","volume":"8","author":"Omote","year":"2018","journal-title":"Sci Rep"},{"key":"2025063005211286400_bib31","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/ckj\/sfac062","article-title":"Anaplastic lymphoma kinase inhibitors and their effect on the kidney","volume":"15","author":"Bonilla","year":"2022","journal-title":"Clin Kidney J"},{"key":"2025063005211286400_bib32","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1080\/0886022X.2021.1930049","article-title":"Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor","volume":"43","author":"Wang","year":"2021","journal-title":"Ren Fail"},{"key":"2025063005211286400_bib33","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.kint.2021.08.022","article-title":"Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition","volume":"100","author":"Bai","year":"2021","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ckj\/sfv149","article-title":"Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network","volume":"9","author":"Wanchoo","year":"2016","journal-title":"Clin Kidney J"},{"key":"2025063005211286400_bib35","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1016\/j.ekir.2023.08.032","article-title":"Capmatinib-associated pseudoacute kidney injury in nonsmall cell lung cancer","volume":"8","author":"Sandoval","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025063005211286400_bib36","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/cpt.1296","article-title":"Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate","volume":"105","author":"Chappell","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2025063005211286400_bib37","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ekir.2021.11.033","article-title":"Clinicopathologic features of acute kidney injury associated with CDK4\/6 inhibitors","volume":"7","author":"Gupta","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025063005211286400_bib38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/ijgc-2019-000714","article-title":"Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors","volume":"30","author":"Dal Molin","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"2025063005211286400_bib39","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/jnci\/djad070","article-title":"Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors","volume":"115","author":"Gupta","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"2025063005211286400_bib40","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1053\/j.ajkd.2020.05.021","article-title":"Nephrotoxicity associated with niraparib","volume":"76","author":"Lazareth","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025063005211286400_bib41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/jcph.1750","article-title":"Tucatinib inhibits renal transporters OCT2 and MATE without impacting renal function in healthy subjects","volume":"61","author":"Topletz-Erickson","year":"2021","journal-title":"J Clin Pharm"},{"key":"2025063005211286400_bib42","doi-asserted-by":"publisher","first-page":"2213778","DOI":"10.1080\/0886022X.2023.2213778","article-title":"A case of pazopanib-induced acute kidney injury, reversible hair depigmentation and radiation recall dermatitis","volume":"45","author":"Li","year":"2023","journal-title":"Ren Fail"},{"key":"2025063005211286400_bib43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4327904","article-title":"Thrombotic thrombocytopenic purpura associated with pazopanib","volume":"2018","author":"Syed","year":"2018","journal-title":"Case Rep Hematol"},{"key":"2025063005211286400_bib44","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2025063005211286400_bib45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/23993693211009238","article-title":"Evaluating predictors of renal injury with sorafenib in hepatocellular carcinoma: a multi-ethnic cohort study","volume":"5","author":"Natsuhara","year":"2021","journal-title":"J Onco-Nephrol"},{"key":"2025063005211286400_bib46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2025063005211286400_bib47","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","article-title":"Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome","volume":"18","author":"Kapiteijn","year":"2007","journal-title":"Ann Oncol"},{"key":"2025063005211286400_bib48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/ndtplus\/sfp037","article-title":"Acute renal failure after treatment with sunitinib in a patient with multiple myeloma","volume":"2","author":"Leung","year":"2009","journal-title":"Clin Kidney J"},{"key":"2025063005211286400_bib49","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.ekir.2018.07.005","article-title":"Case of proteinuria, worsening hypertension, and glomerular endotheliosis with erlotinib and gefitinib","volume":"3","author":"Latcha","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2025063005211286400_bib50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/ndt\/gfx063","article-title":"Neither creatinine- nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents","volume":"33","author":"Vermassen","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025063005211286400_bib51","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1182\/bloodadvances.2021006395","article-title":"Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning","volume":"6","author":"Kutzke","year":"2022","journal-title":"Blood Adv"},{"key":"2025063005211286400_bib52","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1053\/j.ajkd.2023.04.014","article-title":"Onconephrology: core curriculum 2023","volume":"82","author":"Yarandi","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2025063005211286400_bib53","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"2025063005211286400_bib54","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/j.1523-1755.2005.00575.x","article-title":"VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells","volume":"68","author":"Feliers","year":"2005","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib55","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/ckj\/sfad195","article-title":"Management of hypertension in patients with cancer: challenges and considerations","volume":"16","author":"Pandey","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025063005211286400_bib56","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2215\/CJN.05610522","article-title":"How I manage hypertension and proteinuria associated with VEGF inhibitor","volume":"18","author":"Rashidi","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025063005211286400_bib57","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies\u2013focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"2025063005211286400_bib58","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy\u2013related hypertension: a scientific statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"2025063005211286400_bib59","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and prohypertensive antineoplastic therapies in cancer patients","volume":"128","author":"van Dorst","year":"2021","journal-title":"Circ Res"},{"key":"2025063005211286400_bib60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5414\/CN110443","article-title":"Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: a case series and systematic review of the literature","volume":"96","author":"Hilburg","year":"2021","journal-title":"Clin Nephrol"},{"key":"2025063005211286400_bib61","doi-asserted-by":"publisher","first-page":"101081","DOI":"10.1016\/j.tranon.2021.101081","article-title":"Thrombotic microangiopathy in oncology\u2014a review","volume":"14","author":"Val\u00e9rio","year":"2021","journal-title":"Transl Oncol"},{"key":"2025063005211286400_bib62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025063005211286400_bib63","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"2025063005211286400_bib64","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/1078155218774895","article-title":"Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab","volume":"25","author":"Vakiti","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2025063005211286400_bib65","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025063005211286400_bib66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor\u2013associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025063005211286400_bib68","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib69","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025063005211286400_bib70","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2025063005211286400_bib71","doi-asserted-by":"publisher","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025063005211286400_bib72","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025063005211286400_bib73","doi-asserted-by":"publisher","first-page":"e006222","DOI":"10.1136\/jitc-2022-006222","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis","volume":"11","author":"Sise","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025063005211286400_bib74","doi-asserted-by":"publisher","first-page":"e182275","DOI":"10.1172\/JCI182275","article-title":"F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury","volume":"134","author":"Gupta","year":"2024","journal-title":"J Clin Invest"},{"key":"2025063005211286400_bib75","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor\u2013associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib76","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/2399369320945724","article-title":"Renal injury in the setting of immune checkpoint inhibitor: report of a case of hypothyroidism and the role of positron emission tomography","volume":"4","author":"Heybeli","year":"2020","journal-title":"J Onco-Nephrol"},{"key":"2025063005211286400_bib77","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Management of Immune-Checkpoint Inhibitor Related Toxicities","author":"National Comprehensive Cancer Network","year":"2024"},{"key":"2025063005211286400_bib78","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000538274","article-title":"Association of proton pump inhibitor use and immune checkpoint inhibitor mediated acute kidney injury: a meta-analysis and a review of related outcomes","volume":"55","author":"Mohan","year":"2024","journal-title":"Am J Nephrol"},{"key":"2025063005211286400_bib79","doi-asserted-by":"publisher","first-page":"sfad292","DOI":"10.1093\/ckj\/sfad292","article-title":"All-cause and immune checkpoint inhibitor\u2013associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality","volume":"17","author":"Chen","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025063005211286400_bib80","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/ndt\/gfae257","article-title":"Biomarker guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis","volume":"40","author":"Barbir","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2025063005211286400_bib81","doi-asserted-by":"publisher","first-page":"1877415","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"key":"2025063005211286400_bib82","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025063005211286400_bib83","doi-asserted-by":"publisher","first-page":"13322","DOI":"10.3389\/ti.2024.13322","article-title":"Immune checkpoint inhibitor therapy for kidney transplant recipients\u2014a review of potential complications and management strategies","volume":"37","author":"Barbir","year":"2024","journal-title":"Transpl Int"},{"key":"2025063005211286400_bib84","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMra2014530","article-title":"Long-term survival after kidney transplantation","volume":"385","author":"Hariharan","year":"2021","journal-title":"N Engl J Med"},{"key":"2025063005211286400_bib85","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.kint.2020.10.018","article-title":"Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period","volume":"99","author":"Blosser","year":"2021","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib86","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib87","doi-asserted-by":"publisher","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","article-title":"Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review","volume":"20","author":"Portuguese","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2025063005211286400_bib88","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025063005211286400_bib89","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025063005211286400_bib90","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + tacrolimus + prednisone \u00b1 ipilimumab for kidney transplant recipients with advanced cutaneous cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025063005211286400_bib91","doi-asserted-by":"publisher","first-page":"151497","DOI":"10.1016\/j.semnephrol.2024.151497","article-title":"Kidney transplantation in multiple myeloma and monoclonal gammopathy of renal significance","volume":"44","author":"Leung","year":"2024","journal-title":"Semin Nephrol"},{"key":"2025063005211286400_bib92","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"key":"2025063005211286400_bib93","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"2025063005211286400_bib94","doi-asserted-by":"publisher","first-page":"151496","DOI":"10.1016\/j.semnephrol.2024.151496","article-title":"Systemic amyloidosis and kidney transplantation: an update","volume":"44","author":"Anand","year":"2024","journal-title":"Semin Nephrol"},{"key":"2025063005211286400_bib95","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025063005211286400_bib96","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1053\/j.ajkd.2022.03.010","article-title":"Cancer mortality in people receiving dialysis for kidney failure: an Australian and New Zealand cohort study, 1980-2013","volume":"80","author":"Rosales","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025063005211286400_bib97","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"2025063005211286400_bib98","doi-asserted-by":"publisher","first-page":"E458","DOI":"10.1002\/ajh.24464","article-title":"Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation","volume":"91","author":"Havasi","year":"2016","journal-title":"Am J Hematol"},{"key":"2025063005211286400_bib99","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025063005211286400_bib100","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1016\/j.clml.2021.11.002","article-title":"A new reality for multiple myeloma renal failure: US data report on kidney transplant outcomes","volume":"22","author":"Dykes","year":"2022","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"2025063005211286400_bib101","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025063005211286400_bib102","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"key":"2025063005211286400_bib103","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"2025063005211286400_bib104","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/ki.2014.182","article-title":"Mesangial cells as amyloid factory: a unique contribution of animal models","volume":"86","author":"Sirac","year":"2014","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib105","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-023-00806-w","article-title":"Multiple myeloma with acute light chain cast nephropathy","volume":"13","author":"Leung","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025063005211286400_bib106","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025063005211286400_bib107","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.kint.2024.02.027","article-title":"Monoclonal immunoglobulin crystalline nephropathies","volume":"106","author":"Nasr","year":"2024","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib108","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.kint.2021.10.017","article-title":"RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance","volume":"101","author":"Javaugue","year":"2022","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib109","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.ekir.2023.10.013","article-title":"The uncertainty puzzle of monoclonal gammopathy of renal significance without detectable clones","volume":"8","author":"Shah","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025063005211286400_bib110","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int"},{"key":"2025063005211286400_bib111","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.mayocp.2015.01.024","article-title":"Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits","volume":"90","author":"Bhutani","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2025063005211286400_bib112","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025063005211286400_bib113","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025063005211286400_bib114","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + tacrolimus + prednisone \u00b1 ipilimumab for kidney transplant recipients with advanced cutaneous cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf174\/63400124\/sfaf174.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/6\/sfaf174\/63400124\/sfaf174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/6\/sfaf174\/63400124\/sfaf174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:21:19Z","timestamp":1751275279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf174\/8152912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf174","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,29]]},"article-number":"sfaf174"}}